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Shared genetic aetiology of puberty timing between
sexes and with health-related outcomes
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Understanding of the genetic regulation of puberty timing has come largely from studies of
rare disorders and population-based studies in women. Here, we report the largest genomic
analysis for puberty timing in 55,871 men, based on recalled age at voice breaking. Analysis
across all genomic variants reveals strong genetic correlation (0.74, P¼ 2.7 10 70)
between male and female puberty timing. However, some loci show sex-divergent effects,
including directionally opposite effects between sexes at the SIM1/MCHR2 locus
(Pheterogeneity¼ 1.6 10 12). We ﬁnd ﬁve novel loci for puberty timing (Po5 108), in
addition to nine signals in men that were previously reported in women. Newly implicated
genes include two retinoic acid-related receptors, RORB and RXRA, and two genes reportedly
disrupted in rare disorders of puberty, LEPR and KAL1. Finally, we identify genetic correlations
that indicate shared aetiologies in both sexes between puberty timing and body mass index,
fasting insulin levels, lipid levels, type 2 diabetes and cardiovascular disease.
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V
oice breaking describes the drop in resonant frequency
due to elongation of the larynx in response to androgen
exposure1. It is a distinct developmental milestone that
occurs during late puberty in males (typically between Tanner
stages 3 to 4), and age at voice breaking therefore represents a
non-invasive marker for the study of puberty timing in men2.
Age at menarche, the onset of the ﬁrst menstrual bleed, is a
similar marker of pubertal timing in females and has been more
widely studied3. Age at menarche in women has been associated
with a wide range of disease risks, and previous genome-wide
association studies (GWASs) have reported over 100 common
loci and ﬁve low-frequency coding variants, implicating several
previously unsuspected mechanisms involved in the regulation of
puberty timing, including post-transcriptional microRNA
repression, gamma-aminobutyric acid-B (GABA-B) receptor
signalling and nuclear hormone signalling4–7. Those menarche
loci were reportedly enriched for variants also associated with
puberty timing in boys, but those analyses were limited by the
small number of boys with assessment of physical characteristics
of puberty5,6.
Consequently, our understanding of the regulation of puberty
timing in males is derived in large part from studies of rare
disorders of puberty. To date,B20 genes have been implicated in
abnormally delayed or absent puberty, including normosmic
or anosmic hypogonadotrophic hypogonadism (Kallmann
syndrome), while only three genes have been implicated in
precocious puberty8,9. Here, we report the ﬁrst large-scale GWAS
of puberty timing in males, based on recalled age at voice
breaking in men in the 23andMe study10. By combination with
data on recalled age at menarche in women, we show that the
genetic architecture of puberty timing has a substantial shared
component between males and females, which also overlaps the
genetic basis of several health-related traits and diseases.
Results
Genome-wide association signals for age at voice breaking. We
identiﬁed 11 independent genome-wide signiﬁcant (Po5 10 8)
signals for age at voice breaking in men located at nine genomic
loci (Table 1). Of these, nine signals (mapping to seven loci:
in/near LIN28B, MKL2, BSX, TMEM38B, NR4A2, IGSF1 and
ALMS1) are correlated (r240.05) with reported loci for age at
menarche in women5,7. The two novel signals for puberty timing
are located in/near LEPR and KAL1, both of which are disrupted
in rare disorders of puberty8. The strongest common signal
(minor allele frequency (MAF)45%) for voice breaking was at
the LIN28B locus (rs9391253, P¼ 8 10 24) where three
independent signals were identiﬁed (Table 1), which is
consistent with the allelic heterogeneity at this locus reported
for age at menarche5. All signals are common variants, except for
a rare (MAF¼ 1%) intergenic variant near ALMS1, which is
associated with 0.32 year per allele later age at voice breaking, and
is highly correlated with a rare non-synonymous variant in
ALMS1 (rs45501594, T3542S, r2¼ 0.83) that is reportedly
associated with age at menarche in women7.
Genetic overlap between puberty timing in men and women.
To estimate the shared genetic aetiology between timing of
puberty in men and women, we used LD Score Regression11 to
calculate the genome-wide genetic correlation (rg) between age at
voice breaking in men and age at menarche in women. The
observed strong positive correlation (rg¼ 0.74, P¼ 2.7 10 70)
indicates that many variants have similar inﬂuences on puberty
timing in males and females. This sex concordance is illustrated
by comparison of the effect sizes of all genome-wide signiﬁcant
loci for age at menarche/voice breaking (Fig. 1). Only six of the
123 reported age at menarche loci show signiﬁcant sex-discordant
effects on puberty timing (Pheterogeneityo4.0 10 4); these
were rs889122-OLFM2, rs466639-RXRG, rs2688325-CSMD1,
rs1254337-SIX6, rs6555855-SLIT3 and rs9321659-SIM1/MCHR2.
Notably, at the SIM1/MCHR2 locus the reported menarche-age
raising allele is associated with younger age at voice breaking in
men (P¼ 7.9 10 5, Pheterogeneity¼ 1.6 10 12).
Conﬁrmation of novel puberty timing signals. Given the strong
overall genetic correlation between puberty timing loci in men
and women, and the paucity of male puberty timing data
available in similarly sized studies, we sought conﬁrmation of
novel puberty timing loci identiﬁed in men using GWAS data on
age at menarche in women (from a combination of publicly
available HapMap2-imputed data from 182,416 women in the
ReproGen consortium5 and 1,000-Genomes-imputed data from
76,831 additional women in the 23andMe study10,12).
Both of the novel genome-wide signiﬁcant signals for age at
voice breaking in men (in/near LEPR and KAL1) show
directionally concordant associations with age at menarche in
women (Table 1, LEPR P¼ 1.85 10 5; KAL1 2.4 10 4).
However, the LEPR signal (rs140410685 a 3 bp indel) shows a
threefold larger effect on puberty timing in men than in women
(Pheterogeneity¼ 3.7 10 5).
We next attempted to conﬁrm sub-genome-wide signiﬁcant
signals for age at voice breaking (5 10 8oPo1 10 6). Of
the ﬁve signals at this threshold, three were strongly correlated
with reported signals for age at menarche5, showing directionally
concordant associations with puberty timing in both sexes
(rs10980922-ZNF483, rs2282752-WDR6 and rs6681737-NR5A2).
The other two signals (rs9350100-RNF144B/ID4 and rs6560352-
RORB) showed directionally concordant associations with age at
menarche (Po0.01), but with signiﬁcant heterogeneity between
sexes (Table 1). Given this heterogeneity we meta-analysed
the two estimates in a random-effects model. Variants at the
novel RNF144B-ID4 locus reached genome-wide signiﬁcance
for puberty timing in men and women combined. Although
rs6560352 did not reach signiﬁcance in this meta-analysis
(P¼ 2.1 10 6), an uncorrelated variant (rs4237264, r2B0) at
this RORB locus was previously reported as a possible signal for
age at menarche (P¼ 9 10 6)5. In a combined meta-analysis,
we robustly conﬁrmed rs4237264 as a novel signal for puberty
timing in men and women (P¼ 2 10 11).
RORB encodes retinoic acid receptor (RAR)-related orphan
receptor beta; notably RORA and RXRG (encoding retinoid X
receptor gamma) were previously implicated in age at menarche5.
We therefore tested single nucleotide polymorphisms (SNPs)
within 500 kb of the remaining six RAR, RAR-related and
retinoid X receptor (RXR) encoding genes for associations with
puberty timing in our pooled sample of men and women,
identifying one additional novel signal B350 kb downstream
of RXRA (rs416390, P¼ 2 10 8) and a further suggestive
signal B330 kb upstream of RXRB (rs241438, P¼ 5 10 6). In
aggregate, SNPs in or near a reported list of nuclear hormone
receptor genes that contain these RAR-related and RXR genes are
signiﬁcantly enriched for associations with age at voice breaking
in men (P¼ 7 10 3), as reported for age at menarche in
women5.
Genetic correlation between puberty timing and other traits.
To inform the likely aetiological relevance of puberty timing in
men and women to other health-related outcomes, we used LD
Score Regression to test their genetic correlations (rg) with
27 other traits or complex diseases. There is no signiﬁcant
heterogeneity observed in genetic correlations between men and
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women. In men and women combined, signiﬁcant genetic cor-
relations (conservatively adjusted for multiple testing:
Po1.85 10 3 (¼ 0.05/27)) are observed between puberty
timing and nine other traits or disease outcomes (Table 2). The
strongest genetic correlation is with body mass index (BMI;
rg¼  0.34, P¼ 4.6 10 104); further inverse genetic correla-
tions are observed with polycystic ovary syndrome, fasting insulin
levels, type 2 diabetes, triglyceride levels, cardiovascular disease
and bone mineral density; and positive genetic correlations are
observed with high-density lipoprotein cholesterol levels and
adult height.
Discussion
We report a large genetic study of puberty timing in males and
females. Our ﬁndings are the ﬁrst to quantify the strongly shared
genetic basis for puberty timing between sexes, and this is
consistent with the largely sex-concordant effects of disruptive
mutations in rare disorders of puberty8,9. Accordingly, our
ﬁndings support the validity of recalled age at voice breaking in
men as a marker of puberty timing in epidemiological studies,
consistent with the informative prospective assessment of this
phenotype2.
Independent signals at seven loci previously identiﬁed for age
at menarche in women5 (including three independent signals at
the LIN28B locus) passed the genome-wide statistical signiﬁcance
threshold for age at voice breaking in men (Table 1). These
included the strongest reported common and low-frequency
signals for age at menarche at LIN28B and ALMS1, respectively,
and other signals with relatively large effects. This observation is
consistent with the largely shared genetic architecture for puberty
timing between sexes.
The overlapping genetic architecture for puberty timing in men
and women provided the rationale for a pooled meta-analysis
across the sexes. Notably, we identiﬁed two novel signals, near
RORB and RXRA, which add to the reported signals near to
other retinoic acid receptor-related genes, RORA and RXRG5,
and a ﬁfth signal (near RXRB) showed sub-genome-wide
signiﬁcant association with puberty timing. The retinoic acid
receptor-related and retinoid X receptors function as
transcription factors that dimerize and regulate nuclear
receptors to inﬂuence cell differentiation, development,
circadian rhythm and metabolism13. Their receptor partners
include the canonical receptors for oestrogen and androgens
among other hormones and metabolites14, and their
conformational changes may alter receptor sensitivity15.
Collectively these ﬁndings strengthen the evidence for an
aetiological role of retinoic acid and retinoid receptors in the
regulation of puberty timing, although their relative importance
to male versus female puberty remains to be established. Further
studies are also needed to identify functional links between these
allelic signals and speciﬁc gene and protein functions.
Three additional novel signals reached genome-wide signiﬁ-
cance for puberty timing, represented by variants in/near
RNF144B-ID4, LEPR and KAL1. All three were associated with
puberty timing in both men and women, two of which had
stronger effects in males (LEPR and RNF144B-ID4). The signal at
6p22.3 resides in a gene desert with the two nearest genes, ID4
and RNF144B, located 760 kb and 607 kb away, respectively.
Notably, it also lies 852 kb from KDM1B, a gene in the same
family of histone demethlyases highlighted previously for age at
menarche (variants in/near KDM3B, KDM4A and KDM4C
represented genome-wide signiﬁcant signals)5. Variants near
KAL1 on Xp22.31 had not been highlighted by previous GWAS of
female puberty timing due to paucity of X-chromosome data in
those studies. rs5978985 is correlated with a reported signal
for circulating free testosterone concentrations in males (r2¼ 0.35
Table 1 | Genetic variants associated with age at voice breaking in men and age at menarche in women.
Age at VB, N¼55,871 AAM, Max N¼ 259,247 Puberty timing (menþwomen combined), Max N¼315,118
Location SNP (r2)* Allelesw Gene Effect (s.e.) P value Effect (s.e.) P value N Effect (s.e.)z Pﬁxedz Prandomy N Het P||
Genome-wide signiﬁcant signal for VB at a known AAM locus
6q16.3 rs9391253
(0.83)
T/A/0.32 LIN28B 0.12 (0.01) 8.2 10 24 0.12 (0.005) 1.5 10 163 256,338 0.12 (0.004) 5 10 183 — 312,259 0.35
16p13.12 rs246185
(1)
C/T/0.33 MKL2 0.09 (0.01) 5.7 10 14 0.05 (0.005) 4.0 10 25 254,604 0.05 (0.004) 2.1 10 35 — 310,475 2 10 3
11q24.1 rs7110373
(0.64)
T/C/0.51 BSX 0.08 (0.01) 1.4 10 13 0.05 (0.004) 2.3 10 33 256,434 0.05 (0.004) 3.0 1041 — 312,305 0.20
9q31.2 rs9408817
(0.98)
G/A/0.67 TMEM38B 0.07 (0.01) 1.6 10 10 0.10 (0.005) 8.1 1098 256,462 0.09 (0.004) 1.1 10 105 — 312,333 0.06
Xq26.2 rs5932886
(0.42)
T/C/0.82 IGSF1 0.06 (0.01) 1.9 10 10 0.08 (0.01) 8.3 10 12 76,831 0.07 (0.007) 1.5 10 20 — 132,702 0.36
2p13.1 rs35327298
(0.83)
C/T/0.01 ALMS1 0.32 (0.06) 9.4 109 0.24 (0.04) 3.4 108 76,831 0.27 (0.03) 3.2 10 15 — 132,702 0.25
2q24.1 rs142058842
(0.54)
G/C/0.17 NR4A2 0.08 (0.01) 2.2 108 0.05 (0.007) 1.6 10 12 239,327 0.05 (0.006) 5.7 10 15 — 295,198 0.90
Novel genome-wide signiﬁcant signal for VB
1p31.3 rs140410685z I/D/0.82 LEPR 0.09 (0.01) 8.7 10 11 0.03 (0.006) 1.8 10 5 209,761 0.04 (0.006) — 1.4 10 12 265,632 3.7 10 5
Xp22.31 rs5978985 G/T/0.5 KAL1 0.05 (0.008) 2.1 109 0.03 (0.009) 2.4 104 76,831 0.04 (0.006) 4.6 10 12 — 132,702 0.22
Secondary signals
6q16.3# rs187150974 A/T/0.47 LIN28B 0.08 (0.01) 2.3 109 0.11 (0.01) 1.0 10 20 76,831 0.10 (0.009) 2.6 10 30 — 132,702 0.54
6q16.3# rs9391261 T/A/0.22 LIN28B 0.10 (0.02) 5.6 10 10 0.12 (0.01) 4.5 10 24 76,831 0.11 (0.01) 1.8 10 32 — 132,702 0.19
9q21.13 rs6560352** G/A/0.84 RORB 0.07 (0.01) 9.5 10 7 0.02 (0.007) 0.01 209,736 0.03 (0.006) — 2.1 106 265,607 9 104
Additional novel loci for puberty timing in men and women
6p22.3 rs9350100ww C/T/0.19 RNF144B-ID4 0.07 (0.01) 1.3 10 7 0.02 (0.006) 0.003 207,035 0.03 (0.006) — 4.4 108 262,906 4 104
9q21.13 rs4237264 G/A/0.27 RORB 0.03 (0.01) 0.006 0.03 (0.005) 9.3 10 10 207,055 0.03 (0.005) 2.0 10 11 — 262,926 0.98
9q34.2 rs416390 G/C/0.29 RXRA 0.01 (0.01) 0.32 0.03 (0.005) 2 108 256,467 0.02 (0.004) 2.4 10 8 — 312,338 0.26
AAM, age at menarche; VB, voice breaking.
*Pairwise r2 with the lead SNP from Perry et al.5, if a known locus. The age at menarche lead SNPs (in the order as above) are: rs7759938, rs246185, rs1461503, rs10453225, rs762080, rs45501594 and
rs17236969. These age at menarche lead SNPs were used for the combined puberty timing analyses because the voice breaking lead 1,000-Genomes imputed SNPs were often not available in the
Hapmap2-imputed data from Perry et al. The exceptions were at the ALMS1 and IGSF1 loci, where the voice breaking lead SNPs were analysed for age at menarche only in 23andMe data.
wDeﬁned as age at voice breaking increasing-allele/decreasing-allele/increasing-allele frequency.
zTest statistics from ﬁxed-effects inverse variance-weighted meta-analysis.
yP value from a random-effects meta-analysis was calculated where signiﬁcant heterogeneity was detected at a novel locus.
||Test for heterogeneity in effect estimates between age at voice breaking in men and age at menarche in women from ﬁxed-effects models.
zHapMap2 proxy SNP rs2186245 (r2¼ 1) was used for age at menarche and for puberty timing in men and women combined.
#Voice breaking effect estimates for secondary signals are from conditional models, however the menarche and combined estimates are from univariate models.
**HapMap2 proxy SNP rs2007888 (r2¼0.98) was used for age at menarche and for puberty timing in men and women combined.
wwHapMap2 proxy SNP rs2842385 (r2¼0.99) was used for age at menarche and for puberty timing in men and women combined.
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with rs5934505)16 and KAL1 encodes the extracellular matrix
glycoprotein anosmin-1 implicated in the embryonic migration
of gonadotrophin releasing hormone and olfactory neurons.
Deleterious mutations in KAL1 cause X-linked Kallmann
syndrome, characterized by hypogonadotropic hypogonadism
and anosmia8. rs140410685 near LEPR, which encodes the leptin
receptor, is uncorrelated with a reported neighbouring signal for
age at menarche (r2B0 with rs10789181)5, and shows no
reported association with adult BMI in reported GWAS meta-
analyses (rs2186245 r2¼ 1 proxy, PBMI¼ 0.33, N¼ 233,888)17.
In rare disorders of puberty, disruptive mutations usually have
similar effects on puberty timing in both sexes8,9. Notable
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Figure 1 | Scatterplot comparing effect sizes of the same genetic variants on age at menarche in women and age at voice breaking in men.
Dots indicate newly identiﬁed voice breaking or previously reported age at menarche variants. NS, not signiﬁcant.
Table 2 | Genetic correlations between puberty timing and 27 health-related outcomes.
Age at menarche
(n¼209,820)*
Age at voice breaking
(n¼ 55,871)*
Age at menarche and voice
breaking, combined (N¼265,691)*
Outcomew rg s.e. P value rg s.e. P value rg s.e. P value
z
Body mass index (B234k) 0.35 0.02 1.4E91 0.28 0.04 1.9E 13 0.34 0.02 4.6E 104
HDL cholesterol (B100k) 0.17 0.03 3.4E09 0.16 0.06 5.6E03 0.17 0.03 4.1E 11
Polycystic ovary syndrome (B88k) 0.25 0.05 7.2E07 0.43 0.09 4.0E06 0.29 0.04 6.4E 11
Adult height (B253k) 0.13 0.02 2.5E 10 0.06 0.03 9.0E02 0.11 0.02 1.8E 10
Fasting insulin (B52k) 0.23 0.05 3.6E06 0.26 0.09 2.5E03 0.24 0.04 3.4E08
Triglycerides (B97k) 0.12 0.03 5.1E06 0.07 0.06 2.0E01 0.11 0.02 2.7E06
Cardiovascular disease (87k) 0.12 0.04 5.0E03 0.18 0.07 9.3E03 0.13 0.04 1.9E04
Type 2 diabetes (69k) 0.13 0.04 5.2E04 0.03 0.07 7.1E01 0.11 0.03 1.1E03
Lumbar spine BMD (33k) 0.08 0.03 1.4E02 0.12 0.06 3.5E02 0.09 0.03 1.5E03
Femoral neck BMD (33k) 0.08 0.03 1.3E02 0.10 0.05 6.8E02 0.08 0.03 2.2E03
HbA1c (46k) 0.11 0.05 2.1E02 0.16 0.09 7.8E02 0.12 0.04 4.1E03
Fasting glucose (58k) 0.06 0.04 8.7E02 0.11 0.07 9.3E02 0.07 0.03 2.0E02
Bipolar disorder (17k) 0.07 0.04 9.2E02 0.12 0.07 9.1E02 0.08 0.04 2.3E02
Autism (10k) 0.10 0.04 2.3E02 0.04 0.08 6.5E01 0.09 0.04 2.8E02
Schizophrenia (70k) 0.03 0.03 3.1E01 0.11 0.05 1.6E02 0.05 0.02 3.9E02
Birth weight (27k) 0.07 0.05 1.5E01 0.04 0.09 6.7E01 0.06 0.04 1.4E01
Rheumatoid arthritis (26k) 0.04 0.04 3.8E01 0.11 0.09 1.9E01 0.05 0.04 1.7E01
Alzheimer’s disease (54k) 0.04 0.05 4.2E01 0.10 0.10 3.3E01 0.05 0.05 2.5E01
Major depressive disorder (19k) 0.04 0.06 4.7E01 0.11 0.11 3.3E01 0.05 0.05 2.8E01
Crohn’s disease (21k) 0.04 0.03 1.8E01 0.02 0.06 7.5E01 0.03 0.03 3.0E01
Diastolic blood pressure (69k) 0.03 0.03 3.8E01 0.03 0.08 6.6E01 0.03 0.03 3.3E01
ADHD (5k) 0.06 0.08 4.2E01 0.03 0.14 8.5E01 0.05 0.07 4.3E01
Systolic blood pressure (69k) 0.03 0.03 4.5E01 0.01 0.07 8.9E01 0.02 0.03 5.3E01
Ever smoker (74k) 0.01 0.04 7.3E01 0.04 0.07 5.9E01 0.02 0.03 5.7E01
LDL cholesterol (95k) 0.01 0.03 6.4E01 0.00 0.06 9.9E01 0.01 0.03 6.7E01
Anorexia nervosa (18k) 0.03 0.04 4.3E01 0.05 0.07 5.0E01 0.01 0.03 6.8E01
Ulcerative colitis (27k) 0.04 0.05 4.1E01 0.04 0.07 5.7E01 0.01 0.04 7.4E01
ADHD, attention-deﬁcit hyperactivity disorder; BMD, bone mineral density; HDL, high-density lipoprotein; LDL, low-density lipoprotein.
*Sample size in each GWAS for puberty timing.
wSample size in each GWAS for health-related outcomes is shown in parentheses after each outcome name.
zP values below the multiple test-corrected thresholdo1.85 10 3 (¼0.05/27) are highlighted in bold.
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exceptions are rare mutations in the genes that encode the
pituitary hormones, follicle-stimulating hormone and luteinizing
hormone, which disrupt puberty in females but not in males18. In
normal populations, rapid postnatal weight gain predicts earlier
puberty timing in both sexes, but the inﬂuence of low birth weight
is apparent only in females2. We found that only a small minority
of signals showed sex-discordant effects, most notably rs9321659
at the SIM1-MCHR2 locus. SIM1 encodes a transcription factor
regulator of hypothalamic paraventricular nucleus development
and function. Rare deleterious mutations cause hyperphagia and
severe early onset obesity affecting both males and females19;
however, rs9321659 is reportedly not associated with adult BMI
(P¼ 0.56)17. Overall, these data suggest that combining male and
female data genome wide is likely to yield novel shared puberty
loci, but care should be taken to assess for potential heterogeneity
in the effects.
Finally, our observed genetic correlations indicate the relevance
of puberty timing to later life health outcomes in both men and
women. Consistent with traditional epidemiological evidence20–22,
earlier puberty timing was genetically related to higher risks of
adverse health-related outcomes, including higher BMI, polycystic
ovary syndrome, type 2 diabetes, lipid proﬁles and cardiovascular
disease; it was favourable only for bone mineral density. LD score
regression is a powerful tool to identify potential causal
relationships between traits; however, limitations include the
inability to establish causal directions and to adjust for potential-
mediating factors. The relationship between puberty timing and
obesity risk is complex, with plausible bi-directional mechanisms.
Previous studies have reported that genome-wide signiﬁcant
signals for higher BMI, both in combination and individually,
are associated with earlier puberty timing in females5,23,24.
Conversely, in the opposite direction, earlier puberty timing
associated with the LIN28B rs314276 C-allele leads to faster
adolescent weight gain and higher post-pubertal BMI, without
effects on pre-pubertal BMI25. Further studies are required to
explore whether health outcomes related to earlier puberty timing
are fully mediated by higher BMI.
In summary, this large-scale assessment of the genetic
architecture of puberty timing in males quantiﬁes the extent of
shared aetiology between sexes, extends the evidence implicating
retinoic acid-related receptors in the regulation of puberty timing,
and supports the relevance of puberty timing in both sexes to the
aetiologies of various health-related outcomes.
Methods
Genome-wide association study for age at voice breaking. Genome-wide SNP
data were generated from one or more of three genotyping arrays in up to 55,871
men aged 18 or older of European ancestry from the 23andMe study10,12, who
reported their recalled age at voice breaking, by online questionnaire in response to
the question ‘How old were you when your voice began to crack/deepen?’
Participants answered into one of the predeﬁned age bins (under 9, 9–10 years old,
11–12 years old, 13–14 years old, 15–16 years old, 17–18 years old, 19 years old or
older), scored from 0 to 6. Genetic effect estimates from these 2-year bins were re-
scaled to 1-year effect estimates post analysis. We previously validated the accuracy
of this approach by comparing re-scaled 2-year estimates for age at menarche
(recorded in the same way) to those obtained from studies recording age at
menarche by year. No signiﬁcant heterogeneity was detected across these two
approaches for known menarche loci7. 23andMe participants provided informed
consent to take part in this research under a protocol approved by Ethical and
Independent Review Services, an institutional review board accredited by the
Association for the Accreditation of Human Research Protection Programs. Before
imputation, we excluded SNPs with Hardy–Weinberg equilibrium Po10 20, call
rate o95%, or with large allele frequency discrepancies compared with European
1,000 Genomes reference data. Frequency discrepancies were identiﬁed by
computing a 2 2 table of allele counts for European 1,000 Genomes samples and
2,000 randomly sampled 23andMe participants with European ancestry, and
identifying SNPs with a w2 Po10 15. Genotype data were imputed against the
March 2012 ‘v3’ release of 1,000 Genomes reference haplotype panel. Genetic
association results were obtained from linear regression models assuming additive
allelic effects. These models included as covariates—age and the top ﬁve genetically
determined principal components to account for population structure. The
reported SNP association test P values were computed from likelihood ratio tests.
Results were further adjusted for a lambda GC value of 1.069 to correct for any
residual test statistic inﬂation due to population stratiﬁcation. LD score regression
analysis26 also conﬁrmed that principal component correction had appropriately
controlled for inﬂation due to population stratiﬁcation (pre-GC calculated
interceptB1) before the more conservative GC correction.
Independent signals were identiﬁed using a combination of distance-based
clumping and approximate conditional analysis. Firstly, regions were deﬁned on
the basis of physical proximity, with the most strongly associated SNP representing
the association signal for that region. We then tested for the presence of multiple
statistically independent signals in each region using approximate conditional
analysis implemented in GCTA27. Independent signals indicated by SNP P values
o1 10 6 were considered in follow-up analyses. A signal was considered to be
the same as a previously reported menarche locus if it had a pairwise r240.05.
Combined analyses with other puberty data sets. We followed up these selected
SNPs in two additional sources of data: reported publicly available HapMap2
reference panel-imputed GWAS results for age at menarche from 182,416
women in the ReproGen consortium5; and independent 1,000 genomes reference
panel-imputed GWAS data for age at menarche in 76,831 women in the 23andMe
study7,10.
These additional samples were considered in three analytical designs. Firstly, all
data in women (n¼ 259,247) were combined to estimate effects of the individual
selected SNPs on age at menarche, using ﬁxed-effects inverse variance-weighted
meta-analysis with all effect estimates reported on a per year scale. Secondly, for
genetic correlation analyses with age at menarche, women in ReproGen consortium
cohorts genotyped by the custom ‘iCOGs’ array were excluded to obtain a
consistent sample size across GWAS SNPs (leaving data for analysis on 209,820
women). Thirdly, all GWAS results for puberty timing in men and women
(n¼ 315,118) were combined using inverse variance ﬁxed-effects meta-analysis.
LD Score Regression11,26 showed that combining GWAS data from men and
women did not introduce substantial test statistic inﬂation due to possible
relatedness between strata (cross-trait intercept 0.016, s.e. 0.005). Heterogeneity
between men and women for individual SNP associations was quantiﬁed by the I2
statistic generated by METAL software. SNPs that demonstrated heterogeneity
were analysed in a random-effects model implemented by Han and Eskin28.
Genetic correlations. Genetic correlations (rg) were calculated between age at
voice breaking in men, age at menarche in women, and 27 other complex
traits/diseases in publicly available data sets using LD Score Regression11,26.
Data sets used can be downloaded from http://www.med.unc.edu/pgc/downloads.
Sample numbers in the studies of each trait are shown in Table 2. The only
non-publicly available data set used was a polycystic ovary syndrome GWAS
performed on 5,184 self-reported cases and 82,759 controls from the 23andMe
study29. A conservative Bonferroni corrected P value threshold of 0o1.85 10 3
(¼ 0.05/27) was used to deﬁne signiﬁcant associations.
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